Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

A relationship between baseline tumor-infiltrating lymphocytes (TIL) and outcomes has been described in HER2-positive breast cancer. Nevertheless, the magnitude of this association and whether this effect differs based on the type of anti-HER2 agent remain controversial. This meta-analysis investigated the association between baseline TIL and pathologic complete response (pCR) rates in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab and lapatinib either alone or in combination.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer Treat. Rev.

Title: Cancer treatment reviews

Publisher: Elsevier BV

ISSN (Electronic): 1532-1967

ISSN (Print): 0305-7372

Publication date (Electronic): May 02 2017

Volume: 57

Affiliations

[1 ] Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. Electronic address: czsolinas@gmail.com.

[2 ] Unit of Clinical Epidemiology, IRCCS AOU San Martino-IST, Genova, Italy. Electronic address: marcello.ceppi@hsanmartino.it.

[3 ] Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. Electronic address: matteo.lambertini@bordet.be.

[4 ] Medical Oncology, University of Cagliari, Cagliari, Italy. Electronic address: marioscartozzi@gmail.com.

[5 ] Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. Electronic address: laurence.buisseret@bordet.be.

[6 ] Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. Electronic address: soizic.garaud@bordet.be.

[7 ] Breast International Group (BIG), Brussels, Belgium. Electronic address: Debora.Fumagalli@bigagainstbc.org.

[8 ] Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. Electronic address: evandro.azambuja@bordet.be.

[9 ] Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus campus, Wilrijk, Belgium. Electronic address: roberto@salgado.be.

[10 ] Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. Electronic address: christos.sotiriou@bordet.be.

[11 ] Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. Electronic address: karen.willard-gallo@bordet.be.

[12 ] Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. Electronic address: michail.Ignatiadis@bordet.be.

Article

Publisher Item ID: S0305-7372(17)30063-4

DOI: 10.1016/j.ctrv.2017.04.005

PubMed ID: 28525810

SO-VID: cbaf9ab5-1216-4597-98ac-32b38402dc5b

History

Keywords: HER2-postive breast cancer,Lapatinib,Neoadjuvant treatment,Pathologic complete response,Trastuzumab,Tumor-infiltrating lymphocytes

Data availability:

Keywords: HER2-postive breast cancer, Lapatinib, Neoadjuvant treatment, Pathologic complete response, Trastuzumab, Tumor-infiltrating lymphocytes

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

Read this article at

Abstract

Related collections

Road 2 Open Meta

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 262

Cited by 44